SLS 008
Alternative Names: CRTH2 Antagonist - Ligand Pharmaceuticals; SLS-008Latest Information Update: 28 Oct 2025
At a glance
- Originator Ligand Pharmaceuticals
- Developer Ligand Pharmaceuticals; Seelos Therapeutics
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Skin disorder therapies; Small molecules
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic rhinitis; Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Oesophagitis
Most Recent Events
- 28 Oct 2025 No recent reports of development identified for preclinical development in Asthma in USA (PO)
- 28 Oct 2025 No recent reports of development identified for preclinical development in Atopic-dermatitis in USA (PO)
- 28 Oct 2025 No recent reports of development identified for preclinical development in Oesophagitis in USA (PO)